Table 1. Gefitinib, erlotinib, and fludarabine IC50 values determined by MTT assays in ZAP-70+, ZAP-70−, mutated IgV H , and unmutated IgV H primary CLL cells treated for 24 h.
| CLL patients | Gefitinib median IC50 | Erlotinib median IC50 | Fludarabine median IC50 |
|---|---|---|---|
| ZAP-70+ | 4.5 μM (n=22)a | >40.0 μM (n=8) | 5.4 μM (n=14) |
| ZAP-70− | >15.0 μM (n=23) | >40.0 μM (n=10) | 7.0 μM (n=16) |
| Mutated (Mu-) IgVH | 7.0 μM (n=26) | >40.0 μM (n=12) | 7.0 μM (n=23) |
| Unmutated (Un-) IgVH | 8.3 μM (n=13) | >40.0 μM (n=5) | 5.4 μM (n=10) |
| ZAP-70+ and Mu-IgVH | 4.0 μM (n=9) | >40.0 μM (n=2) | 13.2 μM (n=6) |
| ZAP-70+ and Un-IgVH | 6.0 μM (n=11) | >40.0 μM (n=5) | 5.4 μM (n=8) |
a
Statistical significance of gefitinib median IC50 (P<0.05) between ZAP-70+ and ZAP-70− cells.